AAAAAA

   
Results: 1-25 | 26-50 | 51-59
Results: 26-50/59
Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial
Authors: Topol, CE Califf, RM Simes, RJ Van de Werf, F Diaz, R Paolasso, E Aylward, PE Keech, A Klein, W Piegas, L Tomov, I Armstrong, PW Widimsky, P Grande, P Halinen, M Vahanian, A Neuhaus, K Dimas, AP Preda, I Kristinsson, A Tzivoni, D Ardissino, D White, HD Madsen, S Sugrue, D Sadowski, Z Seabra-Gomes, R Apetrei, E Dalby, A Betriu, A Pfisterer, M Verheugt, F Fox, K Bates, ER Gibler, WB Granger, CB Harrington, RA Hochman, JS Holmes, DR Kleiman, NS Lee, KL Moliterno, DJ Newby, LK Ohman, EM Califf, R Newby, K Zillman, L Lee, K Lemons, P McCourt, B Campbell, C Tardiff, B Snapp, J Bassett, K Hodgson, P Hannan, K Kandzari, L Hawkins, S Hinman-Smith, E McDougal, M Raffetto, K Thompson, D Wehrle, T Ange, C Brown, R Grissom, G Heuckel, M McCall, J Pennachi, W Spychala, M Veasey, S Pullium, M Journey, T Quintero, K Mark, D Davidson-Ray, L Diner, L Nelson, C Sowers, C Webb, G Young, M Bhapkar, M Pacchiana, C Sparapani, R Tuttle, R Weaver, D Borzak, S Douthat, L Topol, E Moliterno, D Konczos, L Baishnab, R Baishnab, R Bakos, A Blashford, L Bratsch, J Brown, K Cadorini, E Carlson, J Clemmons, P DelValle, M Drabik, M Fu, G Gates, K Gibson, Y Heil, L Hill, N Klancar, R McHale, B Montague, E Pasca, N Pergi, L Randall, R Rosso, R Sankovich, K Smith, D Wisniewski, L Witkowski, M Zovkic, V Alexander, K Bhatt, D Brener, S Campbell, L Cho, L Cole, C Deedy, M Foody, J Gassler, J Ghaffari, S Haas, G Kapadia, S Lauer, M Lauer, MS Lincoff, M Lutton, S Marso, S Mukherjee, D Patel, V Penn, M Robbins, M Roe, M Sila, C Thamilarasan, M Wagner, G Armstrong, P Bestilny, S Van de Werf, F Budts, W Graux, S Luyten, A Simes, J Keech, A Kava, M Bower, T Chan, S Crampton, L Monro, C Nayak, M Parente, G Riley, V Wilton, D Aylward, P Dolan, S Thomas, C White, H Scott, M Frye, R Alpert, J Bertrand, M Ryan, T Fisher, L Asarch, L Smith, M Lim, L Bokslag, M Chiu, P Chung, J Collins, S Dougherty, C Guimaraes, D Hakim, Z Mathieson, J Montgomery, L Novotny, B Steiner, B Wittke, B
Citation: Ce. Topol et al., Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial, LANCET, 355(9201), 2000, pp. 337-345
Risk stratification and therapeutic decision making in acute coronary syndromes
Authors: Ohman, EM Granger, CB Harrington, RA Lee, KL
Citation: Em. Ohman et al., Risk stratification and therapeutic decision making in acute coronary syndromes, J AM MED A, 284(7), 2000, pp. 876-878
Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation
Authors: Alexander, JH Sparapani, RA Mahaffey, KW Deckers, JW Newby, LK Ohman, EM Corbalan, R Chierchia, SL Boland, JB Simoons, ML Califf, RM Topol, EJ Harrington, RA
Citation: Jh. Alexander et al., Association between minor elevations of creatine kinase-MB level and mortality in patients with acute coronary syndromes without ST-segment elevation, J AM MED A, 283(3), 2000, pp. 347-353
Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease
Authors: Harrington, RA Armstrong, PW Graffagnino, C Van de Werf, F Kereiakes, DJ Sigmon, KN Card, T Joseph, DM Samuels, R Granett, J Chan, R Califf, RM Topol, EJ
Citation: Ra. Harrington et al., Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease, CIRCULATION, 102(7), 2000, pp. 728-735
Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting
Authors: Marso, SP Bhatt, DL Roe, MT Houghtaling, PL Labinaz, M Kleiman, NS Dyke, C Simmoons, ML Califf, RM Harrington, RA Topol, EJ
Citation: Sp. Marso et al., Enhanced efficacy of eptifibatide administration in patients with acute coronary syndrome requiring in-hospital coronary artery bypass grafting, CIRCULATION, 102(24), 2000, pp. 2952-2958
Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition - Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial
Authors: Lincoff, AM Harrington, RA Califf, RM Hochman, JS Guerci, AD Ohman, EM Pepine, CJ Kopecky, SL Kleiman, NS Pacchiana, CM Berdan, LG Kitt, MM Simoons, ML Topol, EJ
Citation: Am. Lincoff et al., Management of patients with acute coronary syndromes in the United States by platelet glycoprotein IIb/IIIa inhibition - Insights from the platelet glycoprotein IIb/IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial, CIRCULATION, 102(10), 2000, pp. 1093-1100
Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease
Authors: Roe, MT Harrington, RA Prosper, DM Pieper, KS Bhatt, DL Lincoff, AM Simoons, ML Akkerhuis, M Ohman, EM Kitt, MM Vahanian, A Ruzyllo, W Karsch, K Califf, RM Topol, EJ
Citation: Mt. Roe et al., Clinical and therapeutic profile of patients presenting with acute coronary syndromes who do not have significant coronary artery disease, CIRCULATION, 102(10), 2000, pp. 1101-1106
Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes
Authors: Kleiman, NS Lincoff, AM Flaker, GC Pieper, KS Wilcox, RG Berdan, LG Lorenz, TJ Cokkinos, DV Simoons, ML Boersma, E Topol, EJ Califf, RM Harrington, RA
Citation: Ns. Kleiman et al., Early percutaneous coronary intervention, platelet inhibition with eptifibatide, and clinical outcomes in patients with acute coronary syndromes, CIRCULATION, 101(7), 2000, pp. 751-757
Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes
Authors: Mark, DB Harrington, RA Lincoff, AM Califf, RM Nelson, CL Tsiatis, AA Buell, H Mahaffey, KW Davidson-Ray, L Topol, EJ
Citation: Db. Mark et al., Cost-effectiveness of platelet glycoprotein IIb/IIIa inhibition with eptifibatide in patients with non-ST-elevation acute coronary syndromes, CIRCULATION, 101(4), 2000, pp. 366-371
Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients
Authors: Boersma, E Pieper, KS Steyerberg, EW Wilcox, RG Chang, WC Lee, KL Akkerhuis, KM Harrington, RA Deckers, JW Armstrong, PW Lincoff, AM Califf, RM Topol, EJ Simoons, ML
Citation: E. Boersma et al., Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation results from an international trial of 9461 patients, CIRCULATION, 101(22), 2000, pp. 2557-2567
Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT
Authors: Dyke, CM Bhatia, D Lorenz, TJ Marso, SP Tardiff, BE Hogeboom, C Harrington, RA
Citation: Cm. Dyke et al., Immediate coronary artery bypass surgery after platelet inhibition with eptifibatide: Results from PURSUIT, ANN THORAC, 70(3), 2000, pp. 866-871
Redefining medical treatment in the management of unstable angina
Authors: Braunwald, E Califf, RM Cannon, CP Fox, KAA Fuster, V Gibler, WB Harrington, RA King, SB Kleiman, NS Theroux, P Topol, EJ Van de Werf, F White, HD Willerson, JT
Citation: E. Braunwald et al., Redefining medical treatment in the management of unstable angina, AM J MED, 108(1), 2000, pp. 41-53
Age and outcome after acute coronary syndromes without persistent ST-segment elevation
Authors: Hasdai, D Holmes, DR Criger, DA Topol, EJ Califf, RM Harrington, RA
Citation: D. Hasdai et al., Age and outcome after acute coronary syndromes without persistent ST-segment elevation, AM HEART J, 139(5), 2000, pp. 858-866
Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide
Authors: Hasdai, D Holmes, DR Criger, DA Topol, EJ Califf, RM Wilcox, RG Paolasso, E Simoons, M Deckers, J Harrington, RA
Citation: D. Hasdai et al., Cigarette smoking status and outcome among patients with acute coronary syndromes without persistent ST-segment elevation: Effect of inhibition of platelet glycoprotein IIb/IIIa with eptifibatide, AM HEART J, 139(3), 2000, pp. 454-460
Interpreting clinical trials in acute coronary syndromes - Proceedings of an international conference held in Madrid, Spain - 30 January 1999 - Foreword
Authors: Flather, MD Harrington, RA
Citation: Md. Flather et Ra. Harrington, Interpreting clinical trials in acute coronary syndromes - Proceedings of an international conference held in Madrid, Spain - 30 January 1999 - Foreword, EUR H J SUP, 1(R), 1999, pp. R1-R2
Clinical trials in acute coronary syndromes: lessons from PURSUIT
Authors: Harrington, RA
Citation: Ra. Harrington, Clinical trials in acute coronary syndromes: lessons from PURSUIT, EUR H J SUP, 1(R), 1999, pp. R28-R34
The PURSUIT results in perspective
Authors: Harrington, RA
Citation: Ra. Harrington, The PURSUIT results in perspective, EUR H J SUP, 1(N), 1999, pp. N26-N29
Use of glycoprotein IIb IIIa inhibition plus fibrinolysis in acute myocardial infarction
Authors: Hudson, MP Greenbaum, AB Harrington, RA Ohman, EM
Citation: Mp. Hudson et al., Use of glycoprotein IIb IIIa inhibition plus fibrinolysis in acute myocardial infarction, J THROMB TH, 7(3), 1999, pp. 241-245
Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada
Authors: Langer, A Fisher, M Califf, RM Goodman, S O'Connor, CM Harrington, RA Fuster, V
Citation: A. Langer et al., Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada, CAN J CARD, 15(10), 1999, pp. 1095-1102
Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention
Authors: Tardiff, BE Califf, RM Tcheng, JE Lincoff, AM Sigmon, KN Harrington, RA Mahaffey, KW Ohman, EM Teirstein, PS Blankenship, JC Kitt, MM Topol, EJ
Citation: Be. Tardiff et al., Clinical outcomes after detection of elevated cardiac enzymes in patients undergoing percutaneous intervention, J AM COL C, 33(1), 1999, pp. 88-96
Recent clinical trials in acute coronary syndromes without persistent ST elevation
Authors: Tolleson, TR Harrington, RA
Citation: Tr. Tolleson et Ra. Harrington, Recent clinical trials in acute coronary syndromes without persistent ST elevation, CURR OPIN C, 14(5), 1999, pp. 403-411
Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States
Authors: Cohen, M Ferguson, JJ Harrington, RA
Citation: M. Cohen et al., Trials of glycoprotein IIb-IIIa inhibitors in non-ST-segment elevation acute coronary syndromes: Applicability to the practice of medicine in the United States, CLIN CARD, 22(10), 1999, pp. 2-12
Eptifibatide in acute coronary syndromes - Reply
Authors: Harrington, RA Simoons, ML Topol, EJ
Citation: Ra. Harrington et al., Eptifibatide in acute coronary syndromes - Reply, N ENG J MED, 340(1), 1999, pp. 61-61
Lamifiban - A viewpoint
Authors: Harrington, RA
Citation: Ra. Harrington, Lamifiban - A viewpoint, DRUGS, 57(2), 1999, pp. 222-222
Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome - The platelet glycoprotein IIb IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience
Authors: McClure, MW Berkowitz, SD Sparapani, R Tuttle, R Kleiman, NS Berdan, LG Lincoff, AM Deckers, J Diaz, R Karsch, KR Gretler, D Kitt, M Simoons, M Topol, EJ Califf, RM Harrington, RA
Citation: Mw. Mcclure et al., Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome - The platelet glycoprotein IIb IIIa in unstable angina: Receptor suppression using integrilin therapy (PURSUIT) trial experience, CIRCULATION, 99(22), 1999, pp. 2892-2900
Risultati: 1-25 | 26-50 | 51-59